Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Mirum Pharmaceuticals Inc (NASDAQ: MIRM) was $64.72 for the day, down -1.75% from the previous closing price of $65.87. In other words, the price has decreased by -$1.75 from its previous closing price. On the day, 1.38 million shares were traded. MIRM stock price reached its highest trading level at $67.45 during the session, while it also had its lowest trading level at $63.95.
Ratios:
Our analysis of MIRM’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.68 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 376.75. For the most recent quarter (mrq), Quick Ratio is recorded 2.97 and its Current Ratio is at 3.13. In the meantime, Its Debt-to-Equity ratio is 1.25 whereas as Long-Term Debt/Eq ratio is at 1.24.
On April 17, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $48.Stifel initiated its Buy rating on April 17, 2024, with a $48 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 11 ’25 when Peetz Christopher sold 40,000 shares for $62.00 per share. The transaction valued at 2,480,000 led to the insider holds 138,641 shares of the business.
CHRISTOPHER PEETZ bought 40,000 shares of MIRM for $2,480,000 on Aug 11 ’25. On Aug 07 ’25, another insider, Howe Jolanda, who serves as the SVP, GLOBAL CONTROLLER of the company, sold 10,000 shares for $58.00 each. As a result, the insider received 580,000 and left with 2,426 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MIRM now has a Market Capitalization of 3251377408 and an Enterprise Value of 3265726464. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.58 while its Price-to-Book (P/B) ratio in mrq is 12.70. Its current Enterprise Value per Revenue stands at 7.61 whereas that against EBITDA is -99.386.
Stock Price History:
The Beta on a monthly basis for MIRM is 0.91, which has changed by 0.55989397 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, MIRM has reached a high of $66.40, while it has fallen to a 52-week low of $36.86. The 50-Day Moving Average of the stock is 25.76%, while the 200-Day Moving Average is calculated to be 40.38%.
Shares Statistics:
MIRM traded an average of 468.90K shares per day over the past three months and 855290 shares per day over the past ten days. A total of 50.06M shares are outstanding, with a floating share count of 40.60M. Insiders hold about 19.18% of the company’s shares, while institutions hold 93.82% stake in the company. Shares short for MIRM as of 1753920000 were 6634186 with a Short Ratio of 14.15, compared to 1751241600 on 6512657. Therefore, it implies a Short% of Shares Outstanding of 6634186 and a Short% of Float of 13.25.
Earnings Estimates
The dynamic stock of Mirum Pharmaceuticals Inc (MIRM) is currently being evaluated by a team of 8.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.14, with high estimates of $0.07 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.34 and -$1.0 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is $0.06, with 9.0 analysts recommending between $1.28 and -$0.74.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $134.16M to a low estimate of $122.3M. As of the current estimate, Mirum Pharmaceuticals Inc’s year-ago sales were $90.38MFor the next quarter, 8 analysts are estimating revenue of $135.87M. There is a high estimate of $140.79M for the next quarter, whereas the lowest estimate is $129.7M.
A total of 9 analysts have provided revenue estimates for MIRM’s current fiscal year. The highest revenue estimate was $513.83M, while the lowest revenue estimate was $491.6M, resulting in an average revenue estimate of $504.24M. In the same quarter a year ago, actual revenue was $336.89MBased on 10 analysts’ estimates, the company’s revenue will be $600.04M in the next fiscal year. The high estimate is $650.83M and the low estimate is $558.04M.
